12,372 trials
Pain, Postoperative
Primary: Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo) — -3.93; -3.87; -3.39 Score on a scale — p=0.018
Asthma
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) — 64; 6 Participants
Multiple Sclerosis
Primary: Change From Baseline on the Symbol Digit Modalities Test (SDMT) — 44.6; 58.5 Total Correct
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase…
Hypercholesterolemia · Atherosclerosis · Statin Adverse Reaction
Primary: Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) — 4.99; -23.46 percent change — p=<0.001
Pleural Empyema
Primary: Time to Hospital Discharge — 9.0; 9.1 days
Hypercholesterolemia · Atherosclerotic Cardiovascular Disease · Statin Adverse Reaction
Primary: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -22.58; -1.17 percent change — p=<0.001
Venous Thromboembolism
Primary: Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period — 1.2; 3.0 Percentage of participants — p=0.1509
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
Hypercholesterolemia
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 71.6; 16.2; 0.2; 4.5 percentage of participants
Lymphoma, Large B-Cell, Diffuse
Primary: Kaplan-Meier Estimate of Progression Free Survival (PFS) — NA; NA months — p=0.2864
Migraine, With or Without Aura
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 21.2; 10.9 percentage of participants — p=< 0.0001
Schizophrenia
Primary: Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Syndrome Scale…
Attention-Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline at Day 15 in , ADHD Symptoms as Measured by Mean Swanson,Kotkin,Agler,M-Flynn, Pelham Rating Scale(SKAMP)-Combined Score Obtained From an Average of…
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 — -0.43; -0.38 percentage of HbA1c